FDA Inspection 1266744 — Hubei Enoray Biopharmaceutical Co., Ltd.
The FDA completed an inspection of Hubei Enoray Biopharmaceutical Co., Ltd. on Mar 13, 2025 in Huanggang. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Mar 13, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Huanggang (China)